Adrian Quartel's most recent trade in Zevra Therapeutics Inc was a trade of 68,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Jan. 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zevra Therapeutics Inc | Adrian Quartel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 68,000 | 68,000 | - | - | Stock Option (right to buy) | |
| Zevra Therapeutics Inc | Adrian Quartel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jan 2025 | 34,000 | 34,000 | - | - | Restricted Stock Unit | |
| Acer Therapeutics Inc | Adrian Quartel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 30,000 | 30,000 | - | - | Employee Stock Option (right to buy) | |
| Acer Therapeutics Inc | Adrian Quartel | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2022 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) |